# PR12 PRD/State Closure

## Goal

Consolidate the accelerated-runtime roadmap state and handoff after PR08 through
PR11.

## Evidence

- PR08 commit: `29daebe`
- PR09 commit: `52e7aec`
- PR10 commit: `04554ca`
- PR11 commit: `55af343`
- Runtime evidence artifact:
  `artifacts/runtime_spine_review/runtime-acceleration-deep-audit.md`

## In Scope

- Mark PR11 complete and PR12 closure complete in `ACCELERATION_PR_LIST.md`.
- Update `PROJECT_STATE.md` and `NEXT_SESSION_PROMPT.md` so the next spec starts
  from refreshed evidence, not stale PR momentum.
- Record closure in `DECISION_LOG.md`.
- Keep `DEPRECATED_IDEAS.md`, validation benchmark docs, and admission RFC links
  consistent.
- Add docs consistency tests for the closure state.

## Out Of Scope

- Do not change runtime code, backend registries, benchmark implementation,
  Rust/CUDA build surface, or dependencies.
- Do not authorize deferred ideas.
- Do not claim smoke artifacts are validation evidence.

## Public Contract

- APIs/config/artifact keys: unchanged.
- Fallback behavior: unchanged.
- Replay/cache impact: unchanged.
- Handoff contract: new implementation specs require refreshed evidence that can
  change a parent-stage decision.

## Acceptance Criteria

- Targeted tests: `tests/test_acceleration_roadmap_docs.py`.
- Full gates: pytest, ruff, `git diff --check`.
- Review loop max: 3.

## Compact CCoT

Question: How should the roadmap continue after PR08-PR11?

Evidence: The recent PRs opened the NN experiment lane, deferred active-agent
layout, and kept zero-copy/Rayon/C++/CUDA as admission-only RFCs.

Inference: The next step should be evidence refresh, not automatic feature
implementation.

Counterevidence checked: Multiple lanes remain plausible, but no lane is
authorized by closure alone.

Decision: Consolidate state and require refreshed evidence before the next spec.

Falsifier: A refreshed atlas or runtime benchmark changes a parent-stage
decision under the existing guardrails.

Next action: Commit closure and leave the workspace ready for the next
evidence-driven spec.
